Over two years' experience with tralokinumab for moderate to-severe atopic dermatitis : three clinical case studies
Halpern, James Akbar, Faraz Cuell, Alexis Sarapuddin, Ben
Halpern, James
Akbar, Faraz
Cuell, Alexis
Sarapuddin, Ben
Citations
Altmetric:
Affiliation
Walsall Healthcare NHS Trust; LEO Pharma
Other Contributors
Publication date
2023-09
Subject
Collections
Research Projects
Organizational Units
Journal Issue
Abstract
Tralokinumab is an anti-interleukin-13 monoclonal antibody approved in several geographical regions for the treatment of moderate-to-severe atopic dermatitis. This manuscript presents three case studies of patients with moderate-to-severe atopic dermatitis who had failed on prior treatments and took part in trials of tralokinumab. Data is available for approximately two years in each patient and indicates that treatment with tralokinumab every two weeks was associated with substantial improvements in patient itch, sleep and quality of life, with feedback from the patients suggesting that this had a meaningful impact on their daily lives.
Citation
Halpern, J., Akbar, F., Cuell, A., & Sarapuddin, B. (2023). Over two years' experience with tralokinumab for moderate to-severe atopic dermatitis: Three clinical case studies. Dermatological Nursing, 22(3), 35.
Type
Article